Gastric Cancer最新文献

{"title":"Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study.","authors":"Eiji Oki, Teppei Yamada, Tomomi Kashiwada, Hideto Sonoda, Masato Kataoka, Hirofumi Kawanaka, Yasushi Tsuji, Akitaka Makiyama, Mitsuhiko Ota, Qingjiang Hu, Koji Ando, Yasuo Tsuda, Mototsugu Shimokawa, Tomoharu Yoshizumi","doi":"10.1007/s10120-026-01731-0","DOIUrl":"10.1007/s10120-026-01731-0","url":null,"abstract":"<p><p>BACKGROUND: Trastuzumab-based chemotherapy is the standard first-line treatment for HER2-positive advanced gastric cancer. While biosimilars of trastuzumab have demonstrated equivalent efficacy in breast cancer, their clinical utility in gastric cancer remains poorly characterized. The TROX study evaluated the efficacy and safety of a trastuzumab biosimilar (CT-P6) combined with SOX or CapeOX in this population. METHODS: This multicenter, open-label, non-comparative phase II trial enrolled patients with HER2-positive unresectable or recurrent gastric cancer who had not received prior chemotherapy. Patients were randomized to receive CT-P6 with either SOX (S-1 and oxaliplatin) or CapeOX (capecitabine and oxaliplatin). The primary endpoint was overall response rate (ORR), with a threshold ORR of 43% based on prior trastuzumab trials. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. RESULTS: From May 2019 to November 2022, 67 patients were randomized; 34 in the SOX arm and 32 in the CapeOX arm were included in the efficacy analysis. The overall ORR was 77.3% (90% CI: 68.8–85.8%), exceeding the predefined threshold. The median PFS and OS were 9.0 months (95% CI: 6.5–10.7) and 18.6 months (95% CI: 15.1–23.1), respectively. Grade 3–4 adverse events included hypokalemia (18.2%), neutropenia (15.2%), anorexia (12.1%), and peripheral neuropathy (10.6%). No treatment-related deaths were reported. CONCLUSIONS: CT-P6 combined with SOX or CapeOX demonstrated high efficacy and manageable toxicity as first-line therapy for HER2-positive gastric cancer. This study supports the clinical use of trastuzumab biosimilars as cost-effective alternatives to originator biologics in gastric cancer treatment.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"588-596"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric cancer secondary prevention in dyspeptic patients.","authors":"Giulia Fiorini, Massimo Rugge, Nimish Vakil, Antonietta D'Errico, Matteo Pavoni, Stefano Guzzinati, Angelo Zullo, Luigi Gatta, Gabriella Massarenti, Beatrice Rosa, Cristina Marchesani, Giulia Collatuzzo, Cinzia Papadia, Giovanni Barbara, Claudio Borghi, Dino Vaira","doi":"10.1007/s10120-026-01732-z","DOIUrl":"10.1007/s10120-026-01732-z","url":null,"abstract":"<p><p>BACKGROUND: In dyspeptic patients without alarm symptoms, the “Test-and-Treat” (TT) strategy aims to alleviate symptoms and prevent adverse outcomes. An alternative workup expands the TT-strategy by incorporating esophagogastroduodenoscopy (Test-Treat-and-Scope [TT-S]). OBJECTIVE: This prospective cross-sectional study provides evidence-based insights into the clinical workup of dyspepsia by applying the TT and TT-S options. DESIGN: In a consecutive cohort of 2171 dyspeptic patients without alarm symptoms, H. pylori (Hp) status was assessed by 13C-Urea Breath Test, Rapid urease test, and histology. Histology profiling was based on six biopsies and included atrophy staging (OLGA-system). RESULTS: Among Hp-positive and Hp-negative patients, the prevalence of mucosal atrophy was 22.2% and 1.3% (p < 0.001), respectively. In the study population, 92.5% did not exhibit atrophic disease (OLGA stage 0). Among Hp-positive patients, mucosal atrophy occurred in 142/640 subjects. Nine in 640 (1.4%) Hp-positive patients presented advanced atrophy (OLGA-stages III-IV), considered at high-risk for gastric cancer. The overall prevalence of high-risk OLGA stages (III-IV) was below 1.5% (all Hp-positive). The mean age of patients with OLGA stages III-IV was 15 years older than that of non-atrophic patients (p < 0.0001). In all atrophic OLGA-stages, Hp-positive subjects dominated over the Hp-negative (test-for-trend; p < 0.0001). None of the Hp-negative subjects showed extensive atrophy (OLGA-stages III-IV). CONCLUSION: In the considered epidemiological context, advanced gastric atrophy (OLGA-stages III-IV), consistently recognized as at risk of cancer development, only occurred in Hp-positive patients over 55 years. These results support the priority of the TT-S-strategy in Hp-positive patients older than 55, even in the absence of alarm symptoms.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"540-549"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial/ethnic and geographic differences in second primary cancers in stomach cancer survivors: a comparative study of U.S. and South Korea.","authors":"Yuntong Wang, Dong-Woo Choi, Sangwon Lee, Jialin Mao, Art Sedrakyan, Xiang Shu, Kui Son Choi, Heejung Chae, Eunji Choi","doi":"10.1007/s10120-026-01728-9","DOIUrl":"10.1007/s10120-026-01728-9","url":null,"abstract":"<p><strong>Background: </strong>Stomach cancer remains the fifth leading cause of cancer death, with racial/ethnic and geographic differences. As survival improves, these survivors face elevated risks of second primary cancers (SPCs). We evaluated SPC risk and post-SPC survival by race/ethnicity and between the U.S. and South Korea.</p><p><strong>Methods: </strong>We analyzed patients with stage I-III stomach cancer (2012-2020) from the U.S. SEER-17 and Korea Cancer Public-Library Database. SPCs were defined as non-gastric cancers diagnosed > 1 year post initial diagnosis. Cumulative SPC incidence was estimated using Aalen-Johansen method to account for competing death. Cox regression assessed survival impact of SPC development.</p><p><strong>Results: </strong>Among 19,595 U.S. and 204,240 Korean patients, 1,050 and 6,908 developed SPCs, respectively. In the U.S., 5-year SPC incidence was highest in Black (7.4% [6.1-8.6]) and lowest in Pacific Islanders (4.5% [2.3-6.7]). Notable heterogeneity in SPC incidence was observed across Asian subgroups, with Korean Americans showing the highest (6.9% [4.7-9.1]) and Filipinos the lowest (4.4% [1.9-7.2]). In contrast, Korean survivors in South Korea had the lowest SPC incidence (3.8% [3.7-3.9]). SPC development was associated with higher mortality (HR = 2.22 [1.96-2.52]), with a stronger effect in Asians (HR = 3.12) than Whites (HR = 1.96; interaction P < 0.1). Among Asian subgroups, SPC development was associated with the highest mortality in Vietnamese (HR = 13.6) and the lowest in Filipino survivors (HR = 1.54; interaction P < 0.01). Among Korean survivors in South Korea, SPC development conferred a modest increase in mortality risk (HR = 1.68 [1.61-1.75]).</p><p><strong>Conclusions: </strong>SPC risk and outcomes in stomach cancer survivors vary by race/ethnicity and country, particularly within Asian subgroups.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"506-518"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the OXNAD1-PTGS2 axis with resveratrol overcomes ferroptosis Inhibition and reverses 5-FU resistance in gastric cancer.","authors":"Jinzhou Wang, Bishuang Xu, Xiaohan Lin, Biyu Chen, Xiaoyan Liu, Wei Wu","doi":"10.1007/s10120-026-01718-x","DOIUrl":"10.1007/s10120-026-01718-x","url":null,"abstract":"<p><strong>Background: </strong>5-Fluorouracil (5-FU) remains a cornerstone of first-line chemotherapy for gastric cancer, yet the emergence of resistance severely compromises its clinical efficacy. Although ferroptosis suppression has been recognized as a pivotal mechanism of chemoresistance, the mitochondrial regulatory processes involved remain poorly understood.</p><p><strong>Methods: </strong>We integrated clinical specimen analysis, in vitro and in vivo functional assays, multi-omics profiling, and molecular docking to delineate the role of the mitochondrial oxidoreductase OXNAD1 in mediating 5-FU resistance in gastric cancer, and to assess the therapeutic potential of the natural polyphenol resveratrol as a chemosensitizing agent.</p><p><strong>Results: </strong>OXNAD1 was found to be significantly overexpressed in gastric cancer tissues and cell lines, correlating with unfavorable prognosis and enhanced 5-FU resistance. Mechanistically, OXNAD1 directly bound to and suppressed the ferroptosis driver PTGS2, thereby attenuating lipid peroxidation and mitochondrial damage, ultimately restraining ferroptosis and promoting drug resistance. Notably, resveratrol disrupted the OXNAD1-PTGS2 interaction by directly binding OXNAD1, reinstating ferroptotic activity, markedly enhancing the cytotoxic effect of 5-FU in resistant cells, and potentiating the antitumor efficacy of 5-FU in xenograft models.</p><p><strong>Conclusion: </strong>The OXNAD1-PTGS2 axis constitutes a critical metabolic-cell death cross-regulatory pathway underlying 5-FU resistance in gastric cancer. Targeting this axis with resveratrol provides a promising combinatorial strategy to overcome chemoresistance.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"561-577"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term quality of life, financial toxicity, and decision regret following therapeutic and prophylactic gastrectomy for cancer.","authors":"Frank G Lee, Jack W Sample, Chun Fan, Robert A Vierkant, Sara K Daniel, Steven Bowers, Nabil Wasif, Mark J Truty, Michael L Kendrick, Cornelius A Thiels, Travis E Grotz","doi":"10.1007/s10120-026-01723-0","DOIUrl":"10.1007/s10120-026-01723-0","url":null,"abstract":"<p><p>BACKGROUND: Long-term quality of life (QoL) for U.S. gastrectomy cancer patients is not well-defined. This study evaluated QoL, financial toxicity, and decision regret > 3 years after gastrectomy. METHODS: A cross-sectional paper survey using SF-8, Postgastrectomy Syndrome Assessment Scale, COmprehensive Score for financial Toxicity (COST), and Decision Regret Scale (DRS) was administered to adults who underwent therapeutic or prophylactic gastrectomy from 2010 to 2020. RESULTS: Of 240 survivors, 117 responded (48.8% response rate). Median age at survey was 68; 57% were male. Median time from surgery to survey was 7.6 years. 30% were prophylactic. Resections were 62% total and 38% partial with half performed minimally invasive. SF-8 physical and mental component scores were comparable to population norms. Highest severity symptom subscales were meal-related distress, dumping, and diarrhea. Total gastrectomy had worse total symptom score (median 1.98 vs. 1.65, p = 0.021) than partial gastrectomy. Dissatisfaction was highest for eating limitations. Median COST score was 33/44 (absent financial toxicity). Gastrectomy affecting employment was reported in 26% with worse associated COST scores (median 26 vs. 34, p = 0.002). Median DRS score was 0/100 with 15% reporting moderate-to-high regret. Regret was not associated with prophylactic gastrectomy, operative approach, complications, or recurrence, however correlated with dissatisfaction (p < 0.001), total symptom burden (p = 0.008), and financial toxicity (p = 0.002). On multivariable analysis, dissatisfaction was the only significant association (p = 0.005). CONCLUSIONS: Gastrectomy regret was associated with dissatisfaction rather than surgical/oncologic factors. Higher symptom burden in total gastrectomy highlights the surgical implications of improved reconstruction techniques and preserving gastric remnant, when possible, on long-term QoL.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"635-649"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147372866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the genetic landscape of hereditary diffuse-type gastric cancer progression.","authors":"Lars J S Kemp, Remco van Cruchten, Robin Lomans, Natasja Rutgers, Lodewijk A A Brosens, Liudmila L Kodach, Jolanda M van Dieren, Tanya M Bisseling, Richarda de Voer, Martijn Gloerich, Chella R S van der Post","doi":"10.1007/s10120-026-01730-1","DOIUrl":"10.1007/s10120-026-01730-1","url":null,"abstract":"<p><p>BACKGROUND: Hereditary diffuse gastric cancer (HDGC), caused by pathogenic variants (PVs) in CDH1, typically presents as early-stage mucosal lesions composed of non-proliferative signet ring cells (SRCs). While loss of E-cadherin initiates tumorigenesis, the somatic genetic alterations driving progression to advanced disease remain poorly understood. OBJECTIVE: Our goal was to identify morphological and genetic changes associated with HDGC progression. DESIGN: We performed whole exome sequencing on 38 gastric tumors from 26 HDGC patients, spanning early to advanced stages, and compared genetic alterations across tumor stages. RESULTS: Early-stage HDGC lesions exhibited minimal somatic alterations, with low tumor mutational burden (TMB) and few cancer-related mutations. In contrast, advanced tumors showed a significant increase in TMB and frequent somatic mutations in CDH1, TP53, and genes involved in TGF-β signaling, cell adhesion, and actomyosin contractility (e.g., SMAD4, FAT4, RHOA). Copy number variations (CNVs) were also more prevalent in advanced tumors, including recurrent loss of 3p and 17p and amplification of oncogenes MYC and MET. CNV profiles varied between tumor regions, indicating intratumoral heterogeneity and potential clonal evolution. CONCLUSION: HDGC progression is marked by a stepwise accumulation of somatic mutations and chromosomal alterations. While early lesions remain genetically quiet, advanced tumors exhibit complex genetic landscapes, including CDH1 inactivation, oncogenic mutations, and CNVs. These findings highlight key molecular events in HDGC progression and may inform future strategies for early detection and targeted intervention.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"527-539"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147528201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term use of potassium-competitive acid blockers and proton pump inhibitors and the risk of metachronous gastric cancer after H. pylori eradication: a multicenter cohort study.","authors":"Yasutoshi Shiratori, Yuntae Kim, Katsuyuki Fukuda, Nobumi Suzuki, Yoku Hayakawa, Yosuke Tsuji, Tsutomu Nishida, Shu Kiyotoki, Tetsuya Sumiyoshi, Kenkei Hasatani, Naohiro Yoshida, Yasuhiko Hamada, Kazuhiro Furukawa, Keiji Ogura, Takuma Okamura, Nobuo Toda, Masahiro Arai, Susan Hutfless, Neha Sharma, Diana Cheung, Ryota Niikura","doi":"10.1007/s10120-025-01702-x","DOIUrl":"10.1007/s10120-025-01702-x","url":null,"abstract":"<p><p>BACKGROUND AND AIMS: Gastric cancer remains a significant health burden, especially in Asia. Potassium-competitive acid blockers (P-CABs) provide stronger acid suppression than proton pump inhibitors (PPIs), but their long-term impact on metachronous gastric cancer (MGC) remains unclear. This study evaluated the incidence and duration-dependent risk of MGC in P-CAB/PPI users. METHODS: This multicenter retrospective cohort study included patients from 15 institutions in Japan who underwent endoscopic or surgical resection for gastric cancer between 2014 and 2022. After exclusions, 7172 patients who had received H. pylori eradication were analyzed. Chronic use of P-CAB/PPI was defined as administration for more than 3 months. The primary outcome was the incidence of MGC. Cox regression models were used, along with subgroup analyses based on duration and initial treatment type (endoscopy versus surgery). RESULTS: During a median follow-up of 5.8 years, MGC developed in 342 patients. The incidence was highest among P-CAB users (20.9 per 1,000 person-years), followed by PPI users (13.5) and non-users (7.1). Both P-CAB and PPI use were independently associated with increased MGC risk (hazard ratio 3.89 and 1.75, respectively). The association between P-CAB use and MGC was stronger with longer durations of use (hazard ratio 3.44 for < 1 year, 3.95 for 1–3 years, and 9.36 for > 3 years) and was particularly evident in the post-endoscopic group (hazard ratio 4.22) in subgroup analyses. CONCLUSIONS: Chronic use of P-CAB/PPI were associated with MGC. Longer duration may be associated with increased risk of MGC. Further studies are warranted to validate these findings.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"347-356"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering the terminology of \"early\" and \"advanced\" gastric cancer: toward a harmonized global lexicon.","authors":"Takeshi Sano, Narikazu Boku, Florian Lordick","doi":"10.1007/s10120-026-01717-y","DOIUrl":"10.1007/s10120-026-01717-y","url":null,"abstract":"<p><p>The term early gastric cancer (EGC), defined as carcinoma confined to the mucosa or submucosa irrespective of lymph node status, has been widely accepted worldwide. In contrast, the terminology surrounding advanced gastric cancer remains inconsistent across regions. In Western oncology, \"advanced cancer\" often denotes unresectable or metastatic disease, whereas \"early-stage cancer\" may include resectable stage II-III tumors. This semantic discrepancy has led to confusion in international communication, clinical trials, and guideline interpretation. We propose a three-tier terminology-early gastric cancer, locally advanced gastric cancer, and advanced gastric cancer-to align the Japanese pathological concept with global clinical staging practice and therapeutic intent.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"321-322"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning.","authors":"Adila Abdulla, Chao Li","doi":"10.1007/s10120-025-01713-8","DOIUrl":"10.1007/s10120-025-01713-8","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"478-479"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metagenomic analysis of the intragastric and oral microbiome associated with gastric carcinogenesis after Helicobacter pylori eradication.","authors":"Masanori Matsumoto, Akiko Shiotani, Motoyasu Osawa, Osamu Handa, Hiroshi Matsumoto, Eiji Umegaki, Hideo Yonezawa, Takako Osaki","doi":"10.1007/s10120-026-01720-3","DOIUrl":"10.1007/s10120-026-01720-3","url":null,"abstract":"<p><p>BACKGROUND: Few reports have investigated bacterial microbiome in relation to gastric cancer after eradication of Helicobacter pylori (H. pylori). We aimed to conduct a genetic analysis of the gastric and oral microbiome, to identify its association with development of gastric cancer after H. pylori eradication. METHODS: The patients with prior endoscopic submucosal dissection (ESD) history after eradication (cancer patients) and control patients after eradication who underwent upper gastrointestinal endoscopy at Kawasaki Medical School Hospital from May 2021 to March 2023 were enrolled. Saliva and gastric mucus samples were collected and profiled by 16S rRNA gene amplicon sequencing. RESULTS: The subjects consisted of 24 cancer patients and 27 controls. The abundance of the genus Rothia in gastric mucus of the cancer patients was significantly higher compared to the controls. Conversely, the genus Parvimonas was significantly less abundant in the cancer patients. These differences in salivary samples between the two groups were not observed. The abundance of the genus Parvimonas in the gastric mucous was associated with the gastric atrophy, but genus Rothia was not. CONCLUSIONS: Genus Rothia may have some influence on carcinogenesis following H. pylori eradication.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"338-346"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}